Product information.

Research output: Contribution to journalArticle

Abstract

The indications, cost, dose, side effects, pharmacokinetics, and drug interactions for soft-gel saquinavir and grepafloxacin are outlined. The bioavailability of soft-gel saquinavir (Fortovase) compared with the hard gel formulation (Invirase) is discussed. Grepafloxacin (Raxar), an oral fluoroquinolone from Glaxo-Wellcome, is active against nearly all strains of S. pneumoniae and will be potentially advantageous for pneumococcal pneumonia in HIV-infected patients. An analysis of Protocol M/333/0021, comparing AZT plus delavirdine (DLV) to AZT plus 3TC and AZT plus 3TC and DLV, is reviewed. A table lists the study results.

Original languageEnglish (US)
Pages (from-to)8-9
Number of pages2
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Volume10
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Saquinavir
Delavirdine
Lamivudine
Gels
Pneumococcal Pneumonia
Fluoroquinolones
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Biological Availability
Pneumonia
Pharmacokinetics
HIV
Costs and Cost Analysis
grepafloxacin

Cite this

@article{29c594e2c42a467db900b4e2f941901c,
title = "Product information.",
abstract = "The indications, cost, dose, side effects, pharmacokinetics, and drug interactions for soft-gel saquinavir and grepafloxacin are outlined. The bioavailability of soft-gel saquinavir (Fortovase) compared with the hard gel formulation (Invirase) is discussed. Grepafloxacin (Raxar), an oral fluoroquinolone from Glaxo-Wellcome, is active against nearly all strains of S. pneumoniae and will be potentially advantageous for pneumococcal pneumonia in HIV-infected patients. An analysis of Protocol M/333/0021, comparing AZT plus delavirdine (DLV) to AZT plus 3TC and AZT plus 3TC and DLV, is reviewed. A table lists the study results.",
author = "John Bartlett",
year = "1998",
language = "English (US)",
volume = "10",
pages = "8--9",
journal = "The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service",
issn = "1551-8396",
publisher = "Johns Hopkins University Press",
number = "1",

}

TY - JOUR

T1 - Product information.

AU - Bartlett, John

PY - 1998

Y1 - 1998

N2 - The indications, cost, dose, side effects, pharmacokinetics, and drug interactions for soft-gel saquinavir and grepafloxacin are outlined. The bioavailability of soft-gel saquinavir (Fortovase) compared with the hard gel formulation (Invirase) is discussed. Grepafloxacin (Raxar), an oral fluoroquinolone from Glaxo-Wellcome, is active against nearly all strains of S. pneumoniae and will be potentially advantageous for pneumococcal pneumonia in HIV-infected patients. An analysis of Protocol M/333/0021, comparing AZT plus delavirdine (DLV) to AZT plus 3TC and AZT plus 3TC and DLV, is reviewed. A table lists the study results.

AB - The indications, cost, dose, side effects, pharmacokinetics, and drug interactions for soft-gel saquinavir and grepafloxacin are outlined. The bioavailability of soft-gel saquinavir (Fortovase) compared with the hard gel formulation (Invirase) is discussed. Grepafloxacin (Raxar), an oral fluoroquinolone from Glaxo-Wellcome, is active against nearly all strains of S. pneumoniae and will be potentially advantageous for pneumococcal pneumonia in HIV-infected patients. An analysis of Protocol M/333/0021, comparing AZT plus delavirdine (DLV) to AZT plus 3TC and AZT plus 3TC and DLV, is reviewed. A table lists the study results.

UR - http://www.scopus.com/inward/record.url?scp=0031604824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031604824&partnerID=8YFLogxK

M3 - Article

C2 - 11365134

AN - SCOPUS:0031604824

VL - 10

SP - 8

EP - 9

JO - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

JF - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

SN - 1551-8396

IS - 1

ER -